304 results match your criteria: "Charite Comprehensive Cancer Center[Affiliation]"
Z Gastroenterol
November 2015
Klinik für Allgemein- Viszeral und Minimalinvasive Chirurgie, Helios Klinikum Krefeld.
BMC Med Ethics
September 2015
Institute for Medical Ethics and History of Medicine, Ruhr-Universität Bochum, Markstraße 258a, D-44799, Bochum, Germany.
Background: Appropriate information and consent has been one of the most intensely discussed topics within the context of biobank research. In parallel to the normative debate, many socio-empirical studies have been conducted to gather experiences, preferences and views of patients, healthy research participants and further stakeholders. However, there is scarcity of literature which connects the normative debate about justifications for different consent models with findings gained in empirical research.
View Article and Find Full Text PDFRadiat Oncol
August 2015
Department of Radiooncology and Radiotherapy, Charité University Hospital Berlin, Translational Radiation Oncology Research Laboratory, Charitéplatz 1, 10117, Berlin, Germany.
The introduction of next-generation sequencing (NGS) in the field of cancer research has boosted worldwide efforts of genome-wide personalized oncology aiming at identifying predictive biomarkers and novel actionable targets. Despite considerable progress in understanding the molecular biology of distinct cancer entities by the use of this revolutionary technology and despite contemporaneous innovations in drug development, translation of NGS findings into improved concepts for cancer treatment remains a challenge. The aim of this article is to describe shortly the NGS platforms for DNA sequencing and in more detail key achievements and unresolved hurdles.
View Article and Find Full Text PDFAnn Oncol
September 2015
Charité Comprehensive Cancer Center, Charité-Universitätsmedizin, Berlin, Germany.
Radiat Oncol
July 2015
Department of Radiation Oncology, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Background: Peritoneal carcinomatosis occurs in different cancer subtypes and is associated with a dismal prognosis. Some doubts remain whether the whole abdomen can be treated by regional hyperthermia, therefore we analyzed feasibility conducting a pilot study.
Methods: A simulation of the abdominopelvic heat distribution in 11 patients with peritoneal carcinomatosis was done using the HyperPlan software and the SIGMA-60 and SIGMA-Eye applicators.
Nature
August 2015
1] Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany. [2] Department of Pathology, University Hospital Cologne, 50937 Cologne, Germany.
We have sequenced the genomes of 110 small cell lung cancers (SCLC), one of the deadliest human cancers. In nearly all the tumours analysed we found bi-allelic inactivation of TP53 and RB1, sometimes by complex genomic rearrangements. Two tumours with wild-type RB1 had evidence of chromothripsis leading to overexpression of cyclin D1 (encoded by the CCND1 gene), revealing an alternative mechanism of Rb1 deregulation.
View Article and Find Full Text PDFAlcohol Alcohol
January 2016
Department of Psychiatry and Psychotherapy, Charité Campus-Mitte, Berlin, Germany Department of Psychiatry, Psychotherapy, Psychosomatic/Gerontopsychiatry, Vivantes, Wenckebach-Hospital, Berlin, Germany
Objective: The aim of this study was to identify if psychological distress may contribute to treatment outcome in alcohol-addicted patients during a follow-up period of 5 months after detoxification.
Methods: As part of a prospective, multicenter, randomized study in relapse prevention, patients' levels of psychological distress were assessed using the Symptome Checklist (SCL-90-R). At study inclusion, all patients were detoxified and showed no more withdrawal symptoms.
Eur J Cancer
August 2015
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. Electronic address:
Squamous cell cancer of the head and neck (SCCHN) is a frequent aggressive malignancy with limited therapeutic options. Increasing evidence suggests that mammalian target of rapamycin (mTOR)-inhibitors might be effective in advanced SCCHN. However, non-invasive biomarkers for early prediction of treatment efficacy are not established in SCCHN.
View Article and Find Full Text PDFGeburtshilfe Frauenheilkd
April 2015
Hepatology
September 2015
Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin, and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
Unlabelled: Curative treatment of intrahepatic cholangiocarcinoma (ICC) and hilar cholangiocarcinoma (Klatskin tumors) is limited to surgical resection or orthotopic liver transplantation. However, not all patients benefit from a surgical approach and suffer from early tumor recurrence. Response to chemotherapy is generally poor and, until today, no targeted therapy could be established.
View Article and Find Full Text PDFLancet Oncol
May 2015
University of California San Diego Moores Cancer Center, La Jolla, CA, USA.
Background: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC) progressing after first-line platinum regimens have a poor prognosis and few treatment options. Afatinib, an irreversible ERBB family blocker, has shown efficacy in a phase 2 study in this setting. We aimed to assess the efficacy and safety of afatinib compared with methotrexate as second-line treatment in patients with recurrent or metastatic HNSCC progressing on or after platinum-based therapy.
View Article and Find Full Text PDFMol Cancer
February 2015
Experimental and Clinical Research Center, Charité University Medicine Berlin and Max-Delbrück-Center for Molecular Medicine, Robert-Rössle-Str.10, 13125, Berlin, Germany.
Background: The metastasis-associated in colon cancer 1 (MACC1) gene has been identified as prognostic biomarker for colorectal cancer (CRC). Here, we aimed at the refinement of risk assessment by separate and combined survival analyses of MACC1 expression with any of the markers KRAS mutated in codon 12 (KRAS G12) or codon 13 (KRAS G13), BRAF V600 mutation and MSI status in a retrospective study of 99 CRC patients with tumors UICC staged I, II and III.
Findings: We showed that only high MACC1 expression (HR: 6.
Ann Surg Oncol
August 2015
Tumor Bank Ovarian Cancer Network (TOC), European Comprehensive Center for Ovarian Cancer, Charité Comprehensive Cancer Center (CCCC), Berlin, Germany,
Purpose: The peritoneal cancer index (PCI) is used to refer gastrointestinal malignancy patients to either palliative or curative management of their peritoneal carcinomatosis. The aim of this retrospective study was to evaluate the prognostic value of the PCI in patients with primary advanced epithelial ovarian cancer (EOC) after complete cytoreductive surgery.
Methods: PCI quantitatively assesses cancer distribution on the peritoneum by calculating tumor sizes in each of 13 abdominopelvic regions.
Eur J Cancer
March 2015
Charité Comprehensive Cancer Center, Working Group for Head and Neck Cancer, Berlin, Germany; Department of Oral and Maxillofacial Surgery, Charité University Medicine, Berlin, Germany.
Background: Increases in incidence of oropharyngeal squamous cell carcinoma (OPSCC) in countries with falling tobacco use have been attributed to a growing role of human papilloma virus (HPV) in the carcinogenesis. Trends of HPV prevalence in populations with persistently high portions of smokers are poorly characterised.
Patients And Methods: Registry data from East Germany were used to determine incidence trends between 1998 and 2011.
Oncoscience
January 2015
Institute of Pathology, University of Heidelberg Medical School, Heidelberg.
Precision medicine approaches have recently been developed that offer therapies targeting mainly single genetic alterations in malignant tumors. However, next generation sequencing studies have shown that tumors normally harbor multiple genetic alterations, which could explain the so far limited successes of personalized medicine, despite considerable benefits in certain cases. Combination therapies may contribute to a solution, but will pose a major challenge for clinical trials evaluating those therapies.
View Article and Find Full Text PDFGenome Med
January 2015
Medical Genomics, UCL Cancer Institute, University College London, London, WC1E 6DD UK.
Background: The use of tumour xenografts is a well-established research tool in cancer genomics but has not yet been comprehensively evaluated for cancer epigenomics.
Methods: In this study, we assessed the suitability of patient-derived tumour xenografts (PDXs) for methylome analysis using Infinium 450 K Beadchips and MeDIP-seq.
Results: Controlled for confounding host (mouse) sequences, comparison of primary PDXs and matching patient tumours in a rare (osteosarcoma) and common (colon) cancer revealed that an average 2.
World J Gastroenterol
January 2015
Susen Burock, Charité Comprehensive Cancer Center, Invalidenstraße 80, 10117 Berlin, Germany.
Aim: To evaluate the diagnostic and prognostic value of circulating Metastasis Associated in Colon Cancer 1 (MACC1) transcripts in plasma of gastric cancer patients.
Methods: We provide for the first time a blood-based assay for transcript quantification of the metastasis inducer MACC1 in a prospective study of gastric cancer patient plasma. MACC1 is a strong prognostic biomarker for tumor progression and metastasis in a variety of solid cancers.
Ann Oncol
March 2015
West-German Cancer Center, University Hospital, Essen, Germany.
Background: Squamous cell carcinoma of the head and neck (SCCHN) is a common disease, which has a poor prognosis after failure of therapy. Activation of the PI3K-AKT-mTOR axis is commonly detected in recurrent or metastatic SCCHN, and provided the rationale for the clinical phase II trial in pretreated SCCHN.
Patients And Methods: The primary end point was the progression-free survival rate (PFR) at 12 weeks.
J Am Med Dir Assoc
February 2015
Research Group on Geriatrics, Charite University Medicine Berlin, Berlin, Germany; Department of Hepatology and Gastroenterology, Charite University Medicine Berlin, Berlin, Germany.
Objectives: We investigated the impact of low phase angle (PhA) values on muscle strength, quality of life, symptom severity, and 1-year mortality in older cancer patients.
Design: Prospective study with 1-year follow-up.
Participants: Cancer patients aged >60 years.
In Vivo
July 2015
Department of Internal Medicine, Herdecke Community Hospital, Herdecke, Germany.
Background: The combination of nab-paclitaxel and gemcitabine is a new effective first-line chemotherapy for patients with metastatic pancreatic cancer. This was demonstrated in the phase III MPACT trial.
Patients And Methods: Four patients with metastatic pancreatic cancer from our clinical practice received combination chemotherapy with nab-paclitaxel at doses from 100 to 125 mg/m(2) and gemcitabine at doses from 800 to 1,000 mg/m(2) on days 1, 8 and 15 of a 28-day cycle.
Oncology
September 2014
Charité Comprehensive Cancer Center, Charité Universitätsmedizin, Berlin, Germany.
Objectives: We aimed to examine the efficacy of two psycho-oncological interventions in anxiety, depression, and self-perceived as well as physiological stress in inpatients with gynaecological cancer.
Methods: Forty-five women were included in the trial. Thirty-five were categorized as being at high risk of anxiety and depression, and were randomized to either a single psycho-oncological therapy session or a single-session relaxation intervention.
Ann Oncol
January 2015
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester; Department of Medical Oncology, Charité Comprehensive Cancer Center, Berlin, Germany. Electronic address:
Circulating tumour cells (CTCs) are cells of solid tumour origin detectable in the peripheral blood. Their occurrence is considered a prerequisite step for establishing distant metastases. Metastatic melanoma was the first malignancy in which CTCs were detected and numerous studies have been published on CTC detection in melanoma at various stages of disease.
View Article and Find Full Text PDFMol Oncol
May 2014
Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; Experimental and Clinical Research Center, Charité University Medicine, Berlin, Germany. Electronic address:
Nonviral gene therapy represents a realistic option for clinical application in cancer treatment. This preclinical study demonstrates the advantage of using the small-size MIDGE(®) DNA vector for improved transgene expression and therapeutic application. This is caused by significant increase in transcription efficiency, but not by increased intracellular vector copy numbers or gene transfer efficiency.
View Article and Find Full Text PDFRecent Results Cancer Res
July 2014
Department of Psychooncology, Charité Comprehensive Cancer Center, Berlin, Germany,
Continuous improvements in the diagnosis and treatment of cancer lead to improved cure rates and longer survival. However, in many patients, the disease becomes chronic. In this context, the patients' quality of life (QOL) becomes a crucial issue.
View Article and Find Full Text PDF